Skip to Main Content

Paper Details

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Clin Cancer Res
13
2022
ADAURA, EGFR, EGFR-mutated (, EGFRm, EGFRm NSCLC, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer, NSCLC, Osimertinib, PCS, Patients, non-small cell lung cancer, osimertinib, patients
Author NameAffiliation
Jonathan W GoldmanDavid Geffen School of Medicine at University of California Los Angeles
Jonathan W GoldmanDavid Geffen School of Medicine at University of California Los Angeles
Thomas John
Frances A ShepherdUniversity Health Network, Princess Margaret Cancer Center and the University of Toronto
Roy S HerbstYale School of Medicine and Yale Cancer Center
  • 1 - 5

Datasets

Release 1.2